Genmab to measure growth hope against bestseller

The outcome of a crucial study comparing drug candidate Hexabody-CD3 and Darzalex could have consequences for Genmab and Janssen’s co-development partnership, says CEO Jan van de Winkel.

Genmab og partneren Janssen planlægger et sammenlignende studie mellem Hexabody-CD38 og Darzalex Faspro. | Photo: PR / Genmab

The potential successor to Genmab’s bestseller Darzalex will soon have to prove its worth against the reigning champion in a head-to-head trial.

Alongside the company’s partner, Janssen, Genmab is planning a comparison study where Hexabody-CD38 will be measured next to Darzalex Faspro on the efficacy in multiple myeloma, a type of bone marrow cancer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs